NCT04492488View on ClinicalTrials.gov

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

October 18, 2022

Study Completion Date

December 31, 2024

Conditions
Advanced Solid TumorsAdvanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Cancer
Interventions
DRUG

MRG002

Administrated intravenously

Trial Locations (2)

77040

MD Anderson Cancer Center, Houston

92868

University of California Irvine Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY